why choose us

First received: June 07, 2023

Clinical Trial: Hidradenitis Suppurativa Study of Izokibep

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hidradenitis Suppurativa

Study Type: INTERVENTIONAL


Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa

Brief Summary: Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity.This study investigates izokibep in subjects with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve subjects, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.

Read more